A photo of Margaret Collins.

Staff Pathologist, Division of Pathology

Director, GI Pathology

Professor, UC Department of Pathology and Laboratory MedicineUC Department of Pediatrics

513-636-4261

513-636-3924

Board Certified

My Biography & Research

Biography

In 2011, Dr. Collins was named one of the Top Doctors in Pathology by U.S. News & World Report.

Clinical Interests

Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders

Academic Affiliation

Professor, UC Department of Pathology and Laboratory MedicineUC Department of Pediatrics

Divisions

Colorectal Disorders, Pathology, Eosinophilic Disorders, Pathology, Eosinophilic Disorders

My Education

BS: Fordham University, NY, 1972.

MD: Georgetown University, Washington, D.C., 1977.

Residency: Pathology, New York Hospital, NY, 1977-80; Pathology, Columbia-Presbyterian Medical Center, NY, 1980-83.

Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, N.Y., 1983-85; Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87.

Certification: Pathology, 1981; Pediatric Pathology, 1991.

My Publications

Selected Publication

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Hirano, I; Dellon, ES; Hamilton, JD; Collins, MH; Peterson, K; Chehade, M; Schoepfer, AM; Safroneeva, E; Rothenberg, ME; Falk, GW; et al. Gastroenterology. 2020; 158:111-122.e10.

Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Haberman, Y; Karns, R; Dexheimer, PJ; Schirmer, M; Somekh, J; Jurickova, I; Braun, T; Novak, E; Bauman, L; Collins, MH; et al. Nature Communications. 2019; 10.

Maintaining outstanding outcomes using response- And biology-based therapy for intermediate-risk neuroblastoma: A report from the children’s oncology group study ANBL0531. Twist, CJ; Schmidt, ML; Naranjo, A; London, WB; Tenney, SC; Marachelian, A; Shimada, H; Collins, MH; Esiashvili, N; Adkins, ES; et al. Journal of Clinical Oncology. 2019; 37:3243-3255.

Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses from a 12-Week, Phase 2, Randomized, Placebo-controlled Trial. Collins, MH; Dellon, ES; Katzka, DA; Hirano, I; Williams, J; Lan, L. American Journal of Surgical Pathology. 2019; 43:1501-1509.

Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Hyams, JS; Thomas, SD; Gotman, N; Haberman, Y; Karns, R; Schirmer, M; Mo, A; Mack, DR; Boyle, B; Griffiths, AM; et al. The Lancet. 2019; 393:1708-1720.

Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration Why Was the Consortium of Eosinophilic Gastrointestinal Disease Researchers Established?. Gupta, SK; Falk, GW; Aceves, SS; Chehade, M; Collins, MH; Dellon, ES; Gonsalves, N; Hirano, I; Mukkuda, VA; Peterson, KA; et al. Gastroenterology. 2019; 156:838-842.

Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. Dellon, ES; Katzka, DA; Collins, MH; Gupta, SK; Lan, L; Williams, J; Hirano, I. Clinical Gastroenterology and Hepatology. 2019; 17:666-673.e8.

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Hirano, I; Collins, MH; Assouline-Dayan, Y; Evans, L; Gupta, S; Schoepfer, AM; Straumann, A; Safroneeva, E; Grimm, M; Smith, H; et al. Gastroenterology. 2019; 156:592-603.e10.

Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Dellon, ES; Liacouras, CA; Molina-Infante, J; Furuta, GT; Spergel, JM; Zevit, N; Spechler, SJ; Attwood, SE; Straumann, A; Aceves, SS; et al. Gastroenterology. 2018; 155:1022-1033.e10.

Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. Aceves, SS; King, E; Collins, MH; Yang, G; Capocelli, KE; Abonia, JP; Atkins, D; Bonis, PA; Carpenter, CL; Dellon, ES; et al. Journal of Allergy and Clinical Immunology. 2018; 142:130-138.e1.